Xindar Biologics reported H1 2026 revenue of 8.618 billion yuan, up 44.8% year-over-year, with net profit of 1.253 billion yuan (IFRS) up 50.2% and non-IFRS net profit of 1.704 billion yuan up 40.5%.
Jin1008/25, 05:03 PM
- 44.8%
- 56.7%
- 50.2%
- 40.5%
Figures as quoted by Jin10